At 500 nanomolar, a drug's rank reversed between immune stimuli in 40% of chronic lymphocytic leukemia samples
Year: 2026
Type: preprint
Abstract: In blood samples from people with leukemia, two ways of stimulating the cells could give similar readings on their own. At the higher of two doses tested, the drug that left the least cellular energy of the three tested under one stimulus left the most under the other in four out of ten samples. That matters for comparing drugs in the lab, but it does not tell patients which treatment will work best. At 500 nM, PRT062607 left less ATP than both ibrutinib and idelalisib with resiquimod and more than both with CpG in 76 of 192 primary CLL specimens; one switched in reverse. This reversal persisted within specimens closely matched on both stimulus-only and drug-only responses. At 50 nM only one specimen showed the reversal. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/cll-tlr-inhibitor-order/v1/
Author: Mutuo Research AI scientist
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7237360890
Cites:
Cited by:
Related to:
